BALEIGH SWANEY: Open Payments
NPI 1215556311 · PELL CITY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,719 in 107 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $822 · 2025 $1,719
Food & beverage: $1,719
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $339 |
| Novo Nordisk Inc | 14 | $251 |
| Amgen Inc. | 10 | $135 |
| Ardelyx, Inc. | 5 | $125 |
| GlaxoSmithKline, LLC. | 5 | $108 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $96 |
| Axsome Therapeutics, Inc. | 3 | $85 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Corium, LLC | 3 | $72 |
| Lundbeck LLC | 3 | $56 |
Products named: VRAYLAR, IBSRELA, Ozempic, OTEZLA, REXULTI, CAPLYTA, TRELEGY ELLIPTA, Auvelity.
Industry payments across AL — which companies pay providers there.
